Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 697065, 5 pages
http://dx.doi.org/10.1155/2015/697065
Clinical Study

Treatment of Prolactinomas in Low-Income Countries

1Department of Endocrinology, Diabetes and Metabolic Diseases “Mladen Sekso”, University Hospital Center “Sestre Milosrdnice”, University of Zagreb Medical School, Vinogradska Cesta 29, 10000 Zagreb, Croatia
2Department of Radiology, University Hospital Center “Sestre Milosrdnice”, Vinogradska Cesta 29, 10000 Zagreb, Croatia
3Department of Neurosurgery, University Hospital Center “Sestre Milosrdnice”, Vinogradska Cesta 29, 10000 Zagreb, Croatia

Received 25 November 2014; Revised 7 January 2015; Accepted 21 January 2015

Academic Editor: Emanuel Christ

Copyright © 2015 Ivan Kruljac et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. F. Casanueva, M. E. Molitch, J. A. Schlechte et al., “Guidelines of the pituitary society for the diagnosis and management of prolactinomas,” Clinical Endocrinology, vol. 65, no. 2, pp. 265–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Melmed, F. F. Casanueva, A. R. Hoffman et al., “Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Webster, G. Piscitelli, A. Polli, C. I. Ferrari, I. Ismail, and M. F. Scanlon, “A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea,” The New England Journal of Medicine, vol. 331, no. 14, pp. 904–909, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kreutzer, R. Buslei, H. Wallaschofski et al., “Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients,” European Journal of Endocrinology, vol. 158, no. 1, pp. 11–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Babey, R. Sahli, I. Vajtai, R. H. Andres, and R. W. Seiler, “Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists,” Pituitary, vol. 14, no. 3, pp. 222–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Verhelst, R. Abs, D. Maiter et al., “Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2518–2522, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Webster, G. Piscitelli, A. Polli et al., “Dose-dependent suppression of serum prolactin by cabergoline in hyperprolinaemia: a placebo controlled, double blind, multicentre study,” Clinical Endocrinology, vol. 37, no. 6, pp. 534–541, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Vroonen, M. L. Jaffrain-Rea, P. Petrossians et al., “Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients,” European Journal of Endocrinology, vol. 167, no. 5, pp. 651–662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Colao, R. Attanasio, R. Pivonello et al., “Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 85–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Petrossians, L. Borges-Martins, C. Espinoza et al., “Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs,” European Journal of Endocrinology, vol. 152, no. 1, pp. 61–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Q. Passos, J. S. Souza, N. R. Musolino, and M. D. Bronstein, “Long-term follow-up of prolactinomas: normoprolactimemia after bromocriptine withdrawl,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, pp. 3573–3582, 2002. View at Google Scholar
  12. J. W. van 't Verlaat, R. J. M. Croughs, M. J. Hendriks, N. J. Bosma, J. W. Nortier, and J. H. Thijssen, “Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study,” Acta Endocrinologica, vol. 112, no. 4, pp. 487–493, 1986. View at Google Scholar · View at Scopus
  13. J. Kharlip, R. Salvatori, G. Yenokyan, and G. S. Wand, “Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2428–2436, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao, “Advances in the treatment of prolactinomas,” Endocrine Reviews, vol. 27, no. 5, pp. 485–534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. O. M. Dekkers, J. Lagro, P. Burman, J. O. Jørgensen, J. A. Romijn, and A. M. Pereira, “Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 43–51, 2010. View at Publisher · View at Google Scholar · View at Scopus